Biota is an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).
In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza.